Clinical Trial Update: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV [Phase 2]

View source ↗

Summary

Phase 2 study investigating a TLR9 agonist combined with broadly neutralizing antibodies to reduce HIV reservoirs and achieve immunological control.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TLR9 agonist (Toll-like receptor 9 agonist)
• bNAbs

Snippet

Sponsor: University of Aarhus | Conditions: HIV-1-infection | Phase 2 | Status: COMPLETED